Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10038782 | 0.83 | TSHR (0.39) | GAAHSD17B10HTTTP53TSHR | |
| SCHEMBL14104694 | 0.83 | TSHR (0.39) | GAAHSD17B10HTTTP53TSHR | |
| SCHEMBL4931482 | 0.81 | PLA2G10 (0.34) | GAAMIF | |
| SCHEMBL28343216 | 0.77 | ITGB1 (0.41) | GAAHTTTSHRMAPT | |
| SCHEMBL11957432 | 0.76 | NPSR1 (0.35) | GAAHSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL23319136 | 0.76 | HSD17B10 (0.41) | GAAHSD17B10 | |
| SCHEMBL13158875 | 0.76 | — | — | |
| SCHEMBL28346386 | 0.75 | GAA (0.42) | GAABRD4EGFRUSP2HSD17B10 | |
| SCHEMBL13612407 | 0.72 | — | — | |
| SCHEMBL762450 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524936-B2 | Manufacturing process for sitagliptin from L-aspartic acid | SOUKUP MILAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524936-B2 | Manufacturing process for sitagliptin from L-aspartic acid | SOUKUP MILAN (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012156888-A1 | MANUFACTURING PROCESS FOR SITAGLIPTIN FROM L-ASPARTIC ACID | DRUG PROCESS LICENSING ASS., LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120123144-A1 | Manufacturing process for sitagliptin from L-aspartic acid | Drug Process Licensing Associates, LLC (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120123144-A1 | Manufacturing process for sitagliptin from L-aspartic acid | Drug Process Licensing Associates, LLC (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123144-A1 | Manufacturing process for sitagliptin from L-aspartic acid | DPP4, DPP9, DPP7 | GAA 293/4885BRD4 4511/4885EGFR 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.